My Treatment Approach: Advancing Treatment Strategies for HER2+ Metastatic Breast Cancer - Episode 8

Ongoing Trial(s) for Intracranial Progression in Advanced HER2+ Breast Cancer

Panelists discuss the design and rationale of the ongoing BRIDGET (NCT05323955) trial, focusing on how its outcomes could potentially shape the future treatment landscape for HER2-positive breast cancer, particularly in patients with brain metastases.

EP. 1: Clinical Scenario 1: A HER2+ mBC Patient With Trastuzumab Deruxtecan With Brain Mets
EP. 2: Clinical Approaches in Treating HER2+ Breast Cancer and Brain Metastases
EP. 3: T-DXd and the DESTINY-Breast12 Trial for HER2+ Advanced BC With or Without Brain Mets
EP. 4: The Impact of Trastuzumab Deruxtecan on Clinical Practice for HER2+ Advanced BC and Brain Mets
EP. 5: The Influence of Systemic Metastases on Treatment Decision-Making for HER2+ BC With Brain Metastases
EP. 6: Management of HER2+ Breast Cancer With Brain Relapse or Progression
EP. 7: HER2CLIMB-02 Trial: Exploring Tucatinib and T-DM1 for HER2+ mBC
Now Viewing
EP. 8: Ongoing Trial(s) for Intracranial Progression in Advanced HER2+ Breast Cancer
EP. 9: Novel and Emerging Therapeutic Strategies for HER2+ Breast Cancer and Brain Metastases

Video content above is prompted by the following:

  • Briefly review the design and rationale for the ongoing BRIDGET (NCT05323955) trial, and how could the outcomes of this trial shape the future treatment landscape?